Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to comply with the study protocol, in the investigator's judgment~* Participation in Study GA39688 or GA39855, including completion of endoscopy and other assessments at Week 24, without discontinuation of study drug~* Completion of eDiary daily assessments for at least 4 out of 7 days in the week prior to the Week 24 visit of Study GA39688 or GA39855~* For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods during the treatment period and for 60 days after the last dose of study drug~Exclusion Criteria:~* Anaphylaxis/hypersensitivity related to study drug in Study GA39688 or GA39855~* Serious adverse events related to study drug in Study GA39688 or GA39855 that the investigator or Sponsor determines may jeopardize the patient's safety if he or she continues in the study~* Uncontrolled epistaxis within Study GA39688 or GA39855~* Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of omalizumab~* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A: Study GA39688 Omalizumab (Type: EXPERIMENTAL): Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
- Cohort A: Study GA39688 Placebo (Type: EXPERIMENTAL): Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
- Cohort B: Study GA39855 Omalizumab (Type: EXPERIMENTAL): Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
- Cohort B: Study GA39855 Placebo (Type: EXPERIMENTAL): Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).